Drugs / AZD5004
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 114 trials | ||||||
| Phase 1 | NCT07444424 | Mar → Jul 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT07455825 | Mar → Jun 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06988553 | Jun → Nov 2025 | obesity disorder, type 2 diabetes mellitus | Eccogene | Completed | No outcome recorded |
| Phase 1 | NCT06942936 | May 2025 → Jan 2026 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06996886 | May → Jul 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06948747 | May → Oct 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06857695 | Mar → May 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06813781 | Dec 2024 → Oct 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06742762 | Dec 2024 → Apr 2025 | impaired renal function disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06703658 | Nov 2024 → Mar 2025 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06555822 | Aug 2024 → Mar 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06293742 | Feb → Apr 2024 | type 2 diabetes mellitus | Eccogene | Completed | No outcome recorded |
| Phase 1 | NCT06268145 | Feb → Mar 2024 | type 2 diabetes mellitus | Eccogene | Completed | No outcome recorded |
| Phase 1 | NCT05654831 | Dec 2022 → Nov 2023 | type 2 diabetes mellitus | Eccogene | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06579105 | Oct 2024 → Dec 2025 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5004 | “Non-clinical and first-in-human characterization of ECC5004/AZD5004, a novel once-daily, oral small-molecule GLP-1 receptor agonist.” PMID 39495140 ↗ Nov 2024 |
| Known as | ECC5004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06268145 ↗ |
| Action | Activate | “a novel once-daily, oral small-molecule GLP-1 receptor agonist” PMID 39495140 ↗ Nov 2024 |
| Modality | Small molecule | “a novel once-daily, oral small-molecule GLP-1 receptor agonist” PMID 39495140 ↗ Nov 2024 |
| Route | Oral | “ECC5004 was orally administered to NHPs for 9 months” PMID 39495140 ↗ Nov 2024 |
| Target | GLP1R | “ECC5004 bound to the hGLP-1R (IC50 = 2.4 nM)” PMID 39495140 ↗ Nov 2024 |